Phaseline

Targets › NFE2L2

NFE2L2 (Nuclear factor erythroid 2-related factor 2): drug programs, companies and trials

4 programs from 4 companies in 6 trials: 3 Phase 2, 2 Phase 3, 1 Phase 1; Neurology, Metabolic and endocrine, Oncology; next expected readout Oct 2027.

Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles. In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex. (UniProt, Q16236)

Open in Phaseline: the race on NFE2L2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiogenOmaveloxolone (BIIB141)
Nuclear factor erythroid 2-related factor 2 activator
NFE2L2Phase 3Friedreich AtaxiaNov 2027
Nanjing Medical UniversityDimethyl Fumarate Enteric-coated Capsules
Nrf2 activator and fumarate derivative; activates nuclear factor erythroid 2-related facto
NFE2L2Phase 3Type 1 Diabetes; Type 1 Diabetes MellitusDec 2028
NYU Langone HealthDRP-104
Glutamine antagonist
NFE2L2, KEAP1Phase 2Non Small Cell Lung CancerOct 2027
University Hospital, LilleDiroximel Fumarate
Nrf2 activator
NFE2L2Phase 2StrokeMay 2029

Conditions

Friedreich Ataxia (2) Type 1 Diabetes (1) Type 1 Diabetes Mellitus (1) Stroke (1) Non Small Cell Lung Cancer (1)

Modalities

small molecule (3), mixed (1)

Companies

Nanjing Medical University (1) University Hospital, Lille (1) Biogen (1) NYU Langone Health (1)

Related targets

KEAP1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.